This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...

Among patients with grade 1 (least aggressive) or grade 2 (more aggressive than grade 1) somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the phase 3 COMPETE ...

There are 3 grades of neuroendocrine tumours (NETs) – grade 1, 2 and 3a: Grade 1 cancers grow slowly. They are low grade. Grade 2 grow at a moderate pace (between 1 and 3). ... European Neuroendocrine ...

Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial, European Journal of ...

A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

This is a subset of neuroendocrine tumors that are low or intermediate grade. Because they start in hormone-producing cells, some lung neuroendocrine tumors can make hormone-like substances called ...

Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...

SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older with pancreatic neuroendocrine tumors. The approval follows promising ...